Skip to main content
. 2019 Jul 4;11(7):939. doi: 10.3390/cancers11070939

Table 4.

Median OS and PFS with respect to ETS and DoR in the two treatment groups.

PFS and OS in Treatment Groups ETS DoR
≥20% <20% p-Value ≥Median <Median p-Value
median PFS (months)
FOLFOXIRI 9.2 4.5 <0.001 9.2 6.7 <0.001
GemNab 7.3 4.9 0.209 7.5 6.4 0.093
median OS (months)
FOLFOXIRI 17.5 9.6 <0.001 19.5 11.5 0.005
GemNab 10.6 10 0.853 10.9 10.6 0.818